AUPH vs PATH
Aurinia Pharmaceuticals Inc (AUPH) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Aurinia Pharmaceuticals Inc (AUPH) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported AUPH revenue for 2024-12-31 was $59.9M. Net income was $1.4M. Revenue was down 11.7% from 2024-09-30 to 2024-12-31. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
AUPH currently screens at market cap $1.03B and trailing P/E 28.1. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the AUPH and PATH stock pages for the full models.
Not investment advice.